Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer

Hofland, Johannes; van Weerden, Wytske M.; Dits, Natasja F.J.; Steenbergen, Jacobie; van Leenders, Geert J.L.H.; Jenster, Guido; Schröder, Fritz H.; de Jong, Frank H.

doi:10.1158/0008-5472.can-09-2092

Cited by 181Prostate Cancer Treatment and ResearchCancer, Lipids, and MetabolismHormonal and reproductive studies

Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer

Open access

Hofland, Johannes, van Weerden, Wytske M., Dits, Natasja F.J., Steenbergen, Jacobie, van Leenders, Geert J.L.H., Jenster, Guido, Schröder, Fritz H., de Jong, Frank H.·2010·Cancer Research

DOI 10.1158/0008-5472.can-09-2092

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Androgen-deprivation therapy for prostate cancer (PC) eventually leads to castration-resistant PC (CRPC). Intratumoral androgen production might contribute to tumor progression despite suppressed serum androgen concentrations. In the present study, we investigated whether PC or CRPC tissue may be capable of intratumoral androgen synthesis. Steroidogenic enzyme mRNAs were quantified in hormonally manipulated human PC cell lines and xenografts as well as in human samples of normal prostate, locally confined and advanced PC, local nonmetastatic CRPC, and lymph node metastases. Overall, the majority of samples showed low or absent mRNA expression of steroidogenic enzymes required for de novo steroid synthesis. Simultaneous but low expression of the enzymes CYP17A1 and HSD3B1, essential for the synthesis of androgens from pregnenolone, could be detected in 19 of 88 patient samples. Of 19 CRPC tissues examined, only 5 samples expressed both enzymes. Enzymes that convert androstenedione to testosterone (AKR1C3) and testosterone to dihydrotestosterone (DHT; SRD5A1) were abundantly expressed. AKR1C3 expression was negatively regulated by androgens in the experimental models and was increased in CRPC samples. Expression of SRD5A1 was upregulated in locally advanced cancer, CRPC, and lymph node metastases. We concluded that intratumoral steroid biosynthesis contributes less than circulating adrenal androgens, implying that blocking androgen production and its intraprostatic conversion into DHT, such as via CYP17A1 inhibition, may represent favorable therapeutic options in patients with CRPC.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-2092

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The contribution of de-novo intratumoral biosynthesis to local androgens has mostly been excluded.
“While the contribution of de-novo intratumoral biosynthesis to local androgens has mostly been excluded (Hofland et al., 2010)”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Hofland et al., 2010

Cancer Statistics, 2008
Jemal, A., Siegel, R. L., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,184 · see citing works
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · see citing works
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · see citing works
Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones
Payne, A. H., & Hales, D. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0030 · Cited by 1,766 · see citing works
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · see citing works
Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419 · see citing works
Molecular biology of steroid hormone synthesis
MILLER, W. L. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-3-295 · Cited by 1,397 · see citing works
Advances in Male Contraception
Page, S. T., Amory, J. K., & Bremner, W. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0041 · Cited by 1,134 · see citing works
Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082 · see citing works
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903 · see citing works
Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747 · see citing works
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
Koivisto, P. A., Kononen, J., Palmberg, C., Tammela, T. L. J., HYYTINEN, E.-R., Isola, J. J., Trapman, J., Cleutjens, K. B. J. M., Noordzij, M. A., Visakorpi, T., et al. (1997) · PubMed · Cited by 717 · see citing works
Intracrinology
Labrie, F. (1991) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(91)90116-a · Cited by 685 · see citing works
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675 · see citing works
Untitled work
(2001) · PubMed · Cited by 500 · see citing works
Prostate cancer
Damber, J., & Aus, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60729-1 · Cited by 418 · see citing works
The backdoor pathway to dihydrotestosterone
Auchus, R. J. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.09.004 · Cited by 347 · see citing works
Adrenal glands of mouse and rat do not synthesize androgens
van Weerden, W. M., Bierings, H. G., Van Steenbrugge, G. J., De Jong, F. H., & Schröder, F. H. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90204-3 · Cited by 260 · see citing works
Self-citation
TMPRSS2:ERG Fusion by Translocation or Interstitial Deletion Is Highly Relevant in Androgen-Dependent Prostate Cancer, But Is Bypassed in Late-Stage Androgen Receptor–Negative Prostate Cancer
Hermans, K. G., van Marion, R., van Dekken, H., Jenster, G. W., van Weerden, W. M., & Trapman, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1871 · Cited by 240 · see citing works
Self-citation
Evolution of the Androgen Receptor Pathway during Progression of Prostate Cancer
Hendriksen, P. J. M., Dits, N. F. J., Kokame, K., Veldhoven, A., van Weerden, W. M., Bangma, C. H., Trapman, J., & Jenster, G. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3082 · Cited by 226 · see citing works
Self-citation
STEROIDS OF ADRENAL ORIGIN METABOLIZED BY HUMAN PROSTATIC TISSUE BOTH IN VIVO AND IN VITRO
Harper, M. E., Pike, A. W., Peeling, W. B., & Griffiths, K. (1974) · Journal of Endocrinology · doi:10.1677/joe.0.0600117 · Cited by 190 · see citing works
Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer
Thomas, L. N., Lazier, C. B., Gupta, R., Norman, R. W., Troyer, D. A., O'Brien, S. P., & Rittmaster, R. S. (2004) · The Prostate · doi:10.1002/pros.20188 · Cited by 179 · see citing works
Development of seven new human prostate tumor xenograft models and their histopathological characterization.
van Weerden, W. M., de Ridder, C. M., Verdaasdonk, C. L., Romijn, J. C., van der Kwast, T., Schröder, F. H., & van Steenbrugge, G. J. (1996) · Europe PMC (PubMed Central) · Cited by 171 · see citing works
Self-citation
A pathway for the metabolism of vitamin D 3 : Unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1)
Guryev, O., Carvalho, R. A., Usanov, S., Gilep, A., & Estabrook, R. W. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336107100 · Cited by 170 · see citing works
Use of nude mouse xenograft models in prostate cancer research
van Weerden, W. M., & Romijn, J. C. (2000) · The Prostate · doi:10.1002/1097-0045(20000601)43:4 · Cited by 141 · see citing works
Localization of Type 5 17 -Hydroxysteroid Dehydrogenase, 3 -Hydroxysteroid Dehydrogenase, and Androgen Receptor in the Human Prostate by in Situ Hybridization and Immunocytochemistry
Elalfy, M., Luu-The, V., Huang, X., Berger, L., Labrie, F., & Pelletier, G. (1999) · Endocrinology · doi:10.1210/endo.140.3.6585 · Cited by 140 · see citing works
Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma
Fung, K.-M., Samara, E. N. S., Wong, C., Metwalli, A., Krlin, R., Bane, B., Liu, C. Z., Yang, J. T., Pitha, J. V., Culkin, D. J., et al. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01048 · Cited by 129 · see citing works
Development of Nonsteroidal Anti-Inflammatory Drug Analogs and Steroid Carboxylates Selective for Human Aldo-Keto Reductase Isoforms: Potential Antineoplastic Agents That Work Independently of Cyclooxygenase Isozymes
Bauman, D. R., Rudnick, S. I., Szewczuk, L. M., Jin, Y., Gopishetty, S. R., & Penning, T. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.006569 · Cited by 124 · see citing works
Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer
Thomas, L. N., Douglas, R. C., Lazier, C. B., Too, C. K. L., Rittmaster, R. S., & Tindall, D. J. (2007) · European Urology · doi:10.1016/j.eururo.2007.10.052 · Cited by 117 · see citing works
Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers
Xu, Y. J., Dalrymple, S. L., Becker, R. E., Denmeade, S. R., & Isaacs, J. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0184 · Cited by 102 · see citing works
Current strategies in the management of hormone refractory prostate cancer
Martel, C. L., Gumerlock, P. H., Meyers, F. J., & Lara, P. N. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)00090-7 · Cited by 97 · see citing works
The Human PC346 Xenograft and Cell Line Panel: A Model System for Prostate Cancer Progression
Marques, R. B., van Weerden, W. M., Erkens‐Schulze, S., de Ridder, C. M., Bangma, C. H., Trapman, J., & Jenster, G. W. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.035 · Cited by 92 · see citing works
Self-citation
Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer
Wako, K., Kawasaki, T., Yamana, K., Suzuki, K. Z., Jiang, S. S., Umezu, H., Nishiyama, T., Takahashi, K., Hamakubo, T., Kodama, T., et al. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.050906 · Cited by 83 · see citing works
Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer
Venkitaraman, R., Thomas, K., Huddart, R. A., Horwich, A., Dearnaley, D. P., & Parker, C. C. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07261.x · Cited by 79 · see citing works
Progress in Understanding Androgen-Independent Prostate Cancer (AIPC): A Review of Potential Endocrine-Mediated Mechanisms
Schröder, F. H. (2008) · European Urology · doi:10.1016/j.eururo.2008.01.049 · Cited by 78 · see citing works
Self-citation
Docetaxel for hormone-refractory prostate cancer – Authors' reply
Damber, J., & Aus, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61617-7 · Cited by 67 · see citing works
The Change in the Dihydrotestosterone Level in the Prostate Before and After Androgen Deprivation Therapy in Connection With Prostate Cancer Aggressiveness Using the Gleason Score
Nishiyama, T., Ikarashi, T., Hashimoto, Y., Wako, K., & Takahashi, K. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.05.138 · Cited by 55 · see citing works
The role of vitamin D and retinoids in controlling prostate cancer progression.
Peehl, D. M., & Feldman, D. I. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100131 · Cited by 54 · see citing works
Androgens, Adrenal Androgen Precursors, and Their Metabolism in Untreated Primary Tumors and Lymph Node Metastases of Human Prostatic Cancer
Klein, H., Bressel, M., Kastendieck, H., & Voigt, K. (1988) · American Journal of Clinical Oncology · doi:10.1097/00000421-198801102-00008 · Cited by 34 · see citing works
Transforming growth factor-β3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma
Djonov, V., Ball, R. K., Graf, S., Mottaz, A. E., Arnold, A., Flanders, K., Studer, U. E., & Merz, V. W. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970501)31:2 · Cited by 22 · see citing works

Flagged first, then by citations

Sorted by citations

Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B. T., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433 · see citing works
Androgen Signaling in Prostate CancerPreprint
Dai, C. S., Heemers, H. V., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 412 · see citing works
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
Yuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P. (2013) · Oncogene · doi:10.1038/onc.2013.235 · Cited by 367 · see citing works
Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer
Liu, W., Chakraborty, B., Safi, R., Kazmin, D. A., Chang, C., & McDonnell, D. P. (2021) · Nature Communications · doi:10.1038/s41467-021-25354-4 · Cited by 344 · see citing works
Intracrine androgen biosynthesis, metabolism and action revisited
Schiffer, L., Arlt, W., & Storbeck, K.-H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.08.016 · Cited by 217 · see citing works
“tumoral biosynthesis to local androgens has mostly been excluded (Hofland et al., 2010), numerous studies have shown that CRPC is dependent on the intracrine conversion of circulating androgen precursors of adrenal origin to active androgens reviewed in (Capper et al.”
Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism
Rižner, T. L., & Penning, T. M. (2014) · Steroids · doi:10.1016/j.steroids.2013.10.012 · Cited by 217 · see citing works
Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
Mitsiades, N., Sung, C. C., Schultz, N. D., Danila, D. C., He, B., Eedunuri, V. K., Fleisher, M., Sander, C., Sawyers, C. L., & Scher, H. I. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1335 · Cited by 196 · see citing works
Androgen action and metabolism in prostate cancer
Green, S. M., Mostaghel, E. A., & Nelson, P. S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.046 · Cited by 182 · see citing works
Androgen regulation of micro‐RNAs in prostate cancer
Waltering, K. K., Porkka, K. P., Jalava, S. E., Urbanucci, A., Kohonen, P. J., Latonen, L., Kallioniemi, O., Jenster, G. W., & Visakorpi, T. (2010) · The Prostate · doi:10.1002/pros.21276 · Cited by 166 · see citing works
Self-citation
Structural and functional biology of aldo-keto reductase steroid transforming enzymes
Penning, T. M., Wangtrakuldee, P., & Auchus, R. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00089 · Cited by 164 · see citing works
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
Cai, C., & Balk, S. P. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0339 · Cited by 158 · see citing works
Aldo-Keto Reductases and Cancer Drug Resistance
Penning, T. M., Jonnalagadda, S. K., Trippier, P. C., & Rižner, T. L. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000122 · Cited by 152 · see citing works
Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights
Byrns, M. C., Jin, Y., & Penning, T. M. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.11.004 · Cited by 144 · see citing works
AKR1C3 as a target in castrate resistant prostate cancer
Adeniji, A. O., Chen, M., & Penning, T. M. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.05.012 · Cited by 143 · see citing works
Aldo–Keto Reductase AKR1C1–AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy
Zeng, C., Chang, L.-L., Ying, M., Cao, J., He, Q., Zhu, H., & Yang, B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00119 · Cited by 138 · see citing works
Clinical relevance of androgen receptor alterations in prostate cancer
Jernberg, E., Bergh, A. R. J., & Wikström, P. (2017) · Endocrine Connections · doi:10.1530/ec-17-0118 · Cited by 137 · see citing works
Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth
Yepuru, M., Wu, Z., Kulkarni, A. L., Yin, F., Barrett, C. M., Kim, J.-H., Steiner, M. S., Miller, D. D., Dalton, J. T., & Narayanan, R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1151 · Cited by 122 · see citing works
AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders
Penning, T. M. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.07.002 · Cited by 117 · see citing works
Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery
Damiano, M. G., Mutharasan, R. K., Tripathy, S., McMahon, K. M., & Thaxton, C. S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.013 · Cited by 117 · see citing works
Steroidogenic Enzymes and Stem Cell Markers Are Upregulated during Androgen Deprivation in Prostate Cancer
Pfeiffer, M. J., Smit, F. P., Sedelaar, J. P. M., & Schalken, J. A. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00143 · Cited by 115 · see citing works
Molecular Alterations during Progression of Prostate Cancer to Androgen Independence
Saraon, P., Jarvi, K. A., & Diamandis, E. P. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165977 · Cited by 115 · see citing works
Androgen receptor and its splice variants in prostate cancer
Haile, S., & Sadar, M. D. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0766-7 · Cited by 113 · see citing works
The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study
Karkera, J. D., Steiner, H., Li, W., Skradski, V., Moser, P. L., Riethdorf, S., Reddy, M. P., Puchalski, T. A., Safer, K., Prabhakar, U., et al. (2011) · The Prostate · doi:10.1002/pros.21362 · Cited by 113 · see citing works
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
Decker, K. F., Zheng, D., He, Y., Bowman, T. A., Edwards, J. R., & Li, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks888 · Cited by 104 · see citing works
Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer
Liedtke, A. J., Adeniji, A. O., Chen, M., Byrns, M. C., Jin, Y., Christianson, D. W., Marnett, L. J., & Penning, T. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017656 · Cited by 106 · see citing works
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer
Devos, G., Devlies, W., Meerleer, G. D., Baldewijns, M. M. L. L., Gevaert, T., Moris, L., Milonas, D., Poppel, H. V., Berghen, C., Everaerts, W., et al. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00514-9 · Cited by 98 · see citing works
Androgen regulation of prostate cancer: Where are we now?
Corona, G., Baldi, E., & Maggi, M. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03347072 · Cited by 98 · see citing works
Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review
Penning, T. M. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1379503 · Cited by 96 · see citing works
A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
Mitsiades, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4414 · Cited by 91 · see citing works
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
Sternberg, C. N., Molina, A., North, S. A., Mainwaring, P. N., Fizazi, K. S., Hao, Y., Rothman, M. L., Gagnon, D. D., Kheoh, T. S., Haqq, C. M., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds585 · Cited by 90 · see citing works
Characterization of Prostate Cancer Bone Metastases According to Expression Levels of Steroidogenic Enzymes and Androgen Receptor Splice Variants
Jernberg, E., Thysell, E., Ylitalo, E. B., Rudolfsson, S. H., Crnalic, S., Widmark, A., Bergh, A. R. J., & Wikström, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077407 · Cited by 89 · see citing works
Aldo-keto Reductase Family 1 Member C3 (AKR1C3) Is a Biomarker and Therapeutic Target for Castration-Resistant Prostate Cancer
Hamid, A. R. A. H., Pfeiffer, M. J., Verhaegh, G. W. C. T., Schaafsma, E., Brandt, A. M., Sweep, F. C. G. J., Sedelaar, J. P. M., & Schalken, J. A. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00296 · Cited by 87 · see citing works
The Role of Estrogen Receptor β in Prostate Cancer
Christoforou, P., CHRISTOPOULOS, P. F., & Koutsilieris, M. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00105 · Cited by 84 · see citing works
Steroid hormone synthetic pathways in prostate cancer.
Mostaghel, E. A. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.16 · Cited by 81 · see citing works
Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1007 · Cited by 75 · see citing works
Mechanisms of Androgen-Independent Prostate Cancer.
Saraon, P., Drabovich, A. P., Jarvi, K. A., & Diamandis, E. P. (2014) · PubMed Central · Cited by 74 · see citing works
ACSL 3 promotes intratumoral steroidogenesis in prostate cancer cells
Migita, T., Takayama, K., Urano, T., Obinata, D., Ikeda, K., Soga, T., Takahashi, S., & Inoue, S. (2017) · Cancer Science · doi:10.1111/cas.13339 · Cited by 74 · see citing works
Crystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3
Flanagan, J. U., Yosaatmadja, Y., Teague, R., Chai, M. Z. L., Turnbull, A. P., & Squire, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043965 · Cited by 71 · see citing works
Mini-review: Foldosome regulation of androgen receptor action in prostate cancer
Cano, L. Q., Lavery, D. N., & Bevan, C. L. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.023 · Cited by 70 · see citing works
The role of adrenal derived androgens in castration resistant prostate cancer
Barnard, M., Mostaghel, E. A., Auchus, R. J., & Storbeck, K. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105506 · Cited by 67 · see citing works
Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer
Mostaghel, E. A., Zhang, A., Hernández, S., Marck, B. T., Zhang, X., Tamae, D., Biehl, H. E., Tretiakova, M., Bartlett, J., Burns, J. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1431 · Cited by 68 · see citing works
Therapy escape mechanisms in the malignant prostate
Santer, F. R., Erb, H. H. H., & McNeill, R. V. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.005 · Cited by 64 · see citing works
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer
Chen, M., Adeniji, A. O., Twenter, B. M., Winkler, J. D., Christianson, D. W., & Penning, T. M. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.085 · Cited by 65 · see citing works
Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer
Fred Saad, C., & Fizazi, K. S. (2015) · Urology · doi:10.1016/j.urology.2015.07.034 · Cited by 64 · see citing works
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3)
Kikuchi, A., Furutani, T., Azami, H., Watanabe, K., Niimi, T., Kamiyama, Y., Kuromitsu, S., Baskin-Bey, E. S., Heeringa, M. J., Ouatas, T., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0130-5 · Cited by 63 · see citing works
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer
Tamae, D., Mostaghel, E. A., Montgomery, B., Nelson, P. S., Balk, S. P., Kantoff, P. W., Taplin, M., & Penning, T. M. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.12.012 · Cited by 61 · see citing works
Castration Induces Up-Regulation of Intratumoral Androgen Biosynthesis and Androgen Receptor Expression in an Orthotopic VCaP Human Prostate Cancer Xenograft Model
Knuuttila, M., Yatkin, E., Kallio, J., Savolainen, S., Laajala, T. D., Aittokallio, T. A., Oksala, R., Häkkinen, M. R., Keski‐Rahkonen, P., Auriola, S. O. K., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.04.010 · Cited by 62 · see citing works
Overexpression of aldo–keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride
Byrns, M. C., Mindnich, R., Duan, L., & Penning, T. M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.12.012 · Cited by 60 · see citing works
Human Steroid Biosynthesis for the Oncologist
Auchus, M., & Auchus, R. J. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3182408567 · Cited by 56 · see citing works
Preoperative hypogonadism is not an independent predictor of high‐risk disease in patients undergoing radical prostatectomy
Salonia, A., Andrea Gallina, A., Briganti, A., Abdollah, F., Suardi, N. R., Umberto Capitanio, A., Colombo, R., Freschi, M., Rigatti, P., & Montorsi, F. (2011) · Cancer · doi:10.1002/cncr.25985 · Cited by 55 · see citing works
Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)
Penning, T. M. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.05.010 · Cited by 55 · see citing works
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Mostaghel, E. A. (2014) · Cancer Management and Research · doi:10.2147/cmar.s39318 · Cited by 55 · see citing works
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression
Tian, Y., Zhao, L., Zhang, H., Liu, X., Zhao, L., Zhao, X., Li, Y., & Li, J. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-42 · Cited by 54 · see citing works
Human hydroxysteroid dehydrogenases and pre-receptor regulation: Insights into inhibitor design and evaluation
Penning, T. M. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.01.009 · Cited by 50 · see citing works
Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)
Adeniji, A. O., Twenter, B. M., Byrns, M. C., Jin, Y., Winkler, J. D., & Penning, T. M. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.010 · Cited by 50 · see citing works
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer
Hu, R., Denmeade, S. R., & Luo, J. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.49 · Cited by 49 · see citing works
Activin A Stimulates AKR1C3 Expression and Growth in Human Prostate Cancer
Hofland, J., van Weerden, W. M., Steenbergen, J., Dits, N. F. J., Jenster, G. W., & de Jong, F. H. (2012) · Endocrinology · doi:10.1210/en.2011-2065 · Cited by 48 · see citing works
Self-citation
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives
Nadiminty, N., & Gao, A. C. (2011) · World Journal of Urology · doi:10.1007/s00345-011-0771-3 · Cited by 47 · see citing works
Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer
Fankhauser, M., Tan, Y., Macintyre, G., Haviv, I., Hong, M. K. H., Nguyen, A., Pedersen, J. S., Costello, A. J., Hovens, C. M., & Corcoran, N. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3483 · Cited by 48 · see citing works
Hormones and prostate carcinogenesis: Androgens and estrogens
Bosland, M., & Mahmoud, A. M. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.90678 · Cited by 47 · see citing works
Androgen synthesis in prostate cancer: do all roads lead to Rome?
Stuchbery, R., McCoy, P. J., Hovens, C. M., & Corcoran, N. M. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.221 · Cited by 46 · see citing works
Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis
Kumagai, J., Hofland, J., Erkens‐Schulze, S., Dits, N. F. J., Steenbergen, J., Jenster, G. W., Homma, Y., de Jong, F. H., & van Weerden, W. M. (2013) · The Prostate · doi:10.1002/pros.22655 · Cited by 46 · see citing works
Self-citation
Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor
Adeniji, A. O., Uddin, M. J., Zang, T., Tamae, D., Wangtrakuldee, P., Marnett, L. J., & Penning, T. M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00160 · Cited by 45 · see citing works
Circulating steroid hormone variations throughout different stages of prostate cancer
Snaterse, G., Visser, J. A., Arlt, W., & Hofland, J. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0155 · Cited by 44 · see citing works
Self-citation
Pharmacological Targeting of Constitutively Active Truncated Androgen Receptor by Nigericin and Suppression of Hormone-Refractory Prostate Cancer Cell Growth
Mashima, T., Okabe, S., & Seimiya, H. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064790 · Cited by 45 · see citing works
Androgen biosynthesis in castration-resistant prostate cancer
Penning, T. M. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0109 · Cited by 44 · see citing works
Characterization of Polybrominated Diphenyl Ether Toxicity in Wistar Han Rats and Use of Liver Microarray Data for Predicting Disease Susceptibilities
Dunnick, J. K., Brix, A., CUNNY, H. C., Vallant, M. K., & Shockley, K. R. (2012) · Toxicologic Pathology · doi:10.1177/0192623311429973 · Cited by 43 · see citing works
GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer
Labrie, F. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0165 · Cited by 42 · see citing works
SULT2B1b Sulfotransferase: Induction by Vitamin D Receptor and Reduced Expression in Prostate Cancer
Seo, Y., Mirkheshti, N., Song, C. S., Kim, S., Dodds, S. G., Ahn, S., Christy, B. A., Mendez-Meza, R., Ittmann, M., Abboud‐Werner, S. L., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1369 · Cited by 41 · see citing works
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature
Bird, I. M., & Abbott, D. H. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.021 · Cited by 43 · see citing works
Androgen dynamics and serum PSA in patients treated with abiraterone acetate
Ryan, C. J., Peng, W., Kheoh, T. S., Welkowsky, E., Haqq, C. M., Chandler, D. W., Scher, H. I., & Molina, A. (2014) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.8 · Cited by 39 · see citing works
“Getting from Here to There”-Mechanisms and Limitations to the Activation of the Androgen Receptor in Castration-Resistant Prostate Cancer
Sharifi, N., McPhaul, M. J., & Auchus, R. J. (2010) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181ff6bb8 · Cited by 36 · see citing works
Cholesterol as a Potential Target for Castration-Resistant Prostate Cancer
Twiddy, A. L., Leon, C. G., & Wasan, K. M. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0210-y · Cited by 39 · see citing works
Evidence for Steroidogenic Potential in Human Prostate Cell Lines and Tissues
Bennett, N. J., Hooper, J. D., Lambie, D., Lee, C. S., Yang, T., Vesey, D. A., Samaratunga, H., Johnson, D. W., & Gobe, G. C. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.009 · Cited by 37 · see citing works
The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells
Fan, L., Peng, G., Hussain, A., Fazli, L., Guns, E. S. T., Gleave, M. E., & Qi, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.662155 · Cited by 36 · see citing works
Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism
Shih, J.-W., Wang, L., Hung, C.-L., Kung, H.-J., & Hsieh, C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226138 · Cited by 36 · see citing works
Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)
Zang, T., Verma, K., Chen, M., Jin, Y., Trippier, P. C., & Penning, T. M. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.12.015 · Cited by 36 · see citing works
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate
Khanim, F. L., Davies, N., Veliça, P., Hayden, R., Ride, J. P., Pararasa, C., Chong, M., Günther, U. L., Veerapen, N., Winn, P. J., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.83 · Cited by 35 · see citing works
Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer
Zhou, J., Wang, Y., Wu, D., Wang, S., Chen, Z., Xiang, S., & Chan, F. L. (2021) · Oncogene · doi:10.1038/s41388-021-01737-1 · Cited by 36 · see citing works
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer
Yin, Y. D., Fu, M., Brooke, D. G., Heinrich, D. M., Denny, W. A., & Jamieson, S. M. F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00159 · Cited by 33 · see citing works
Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer
Johnson, B. M. (2010) · The Open Prostate Cancer Journal · doi:10.2174/1876822901003010078 · Cited by 32 · see citing works
Alternative splicing in prostate cancer progression and therapeutic resistance
Rawat, C., & Heemers, H. V. (2024) · Oncogene · doi:10.1038/s41388-024-03036-x · Cited by 32 · see citing works
Biomarkers for determination prostate cancer: implication for diagnosis and prognosis
Žiaran, S., Nováková, Z. V., Böhmer, D., & Danišovič, Ľ. (2015) · Neoplasma · doi:10.4149/neo_2015_082 · Cited by 31 · see citing works
Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer
Asangani, I. A., Blair, I. A., Duyne, G. D. V., Hilser, V. J., Moiseenkova‐Bell, V. Y., Plymate, S. R., Sprenger, C. C. T., Wand, A. J., & Penning, T. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.012411 · Cited by 33 · see citing works
De novo steroid biosynthesis in human prostate cell lines and biopsies
Sakai, M., Martinez-Arguelles, D. B., Aprikian, A. G., Magliocco, A. M., & Papadopoulos, V. (2016) · The Prostate · doi:10.1002/pros.23146 · Cited by 31 · see citing works
Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
Zhang, T., Zhu, J., George, D. J., & Armstrong, A. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.995090 · Cited by 30 · see citing works
Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3
Yu, X., Yan, J., Li, Y., Cheng, J., Zheng, L., Fu, T., & Zhu, Y. (2023) · Food & Nutrition Research · doi:10.29219/fnr.v67.9024 · Cited by 29 · see citing works
Targeting sex steroid biosynthesis for breast and prostate cancer therapy
POUTANEN, M. H., Thulin, M. H., & Härkönen, P. L. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00609-y · Cited by 28 · see citing works
Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome
Hofland, J., de Herder, W. W., Derks, L., Hofland, L. J., van Koetsveld, P. M., de Krijger, R. R., van Nederveen, F. H., Horvath, A., Stratakis, C. A., de Jong, F. H., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0594 · Cited by 26 · see citing works
Self-citation
Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity
Ding, G., Wang, J., Feng, C., Jiang, H., Xu, J., & Ding, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.11790 · Cited by 26 · see citing works
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention
Pippione, A. C., Boschi, D., Pors, K., Oliaro‐Bosso, S., & Lolli, M. L. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.44 · Cited by 27 · see citing works
Aldo-keto reductases: Role in cancer development and theranostics
Nagini, S., Kallamadi, P. R., Tanagala, K. K. K., & Reddy, G. B. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.049918 · Cited by 25 · see citing works
Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis
Thulin, M. H., Nilsson, M., Thulin, P., Céraline, J., Ohlsson, C., Damber, J., & Welén, K. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.11.013 · Cited by 26 · see citing works
Screening, synthesis, crystal structure, and molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as novel AKR1C3 inhibitors
Zheng, X., Jiang, Z., Li, X., Zhang, C., Li, Z., Wu, Y., Wang, X., Zhang, C., Luo, H., Xu, J., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.10.044 · Cited by 24 · see citing works
Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts
Huhtaniemi, R., Oksala, R., Knuuttila, M., Mehmood, A., Aho, E., Laajala, T. D., Nicorici, D., Aittokallio, T. A., Laiho, A., Elo, L. L., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.07.029 · Cited by 23 · see citing works
Intracrinology-revisited and prostate cancer
Penning, T. M., & Detlefsen, A. J. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105499 · Cited by 22 · see citing works
Gene Expression Alterations during Development of Castration-Resistant Prostate Cancer Are Detected in Circulating Tumor Cells
Josefsson, A., Larsson, K., Freyhult, E., Damber, J., & Welén, K. (2019) · Cancers · doi:10.3390/cancers12010039 · Cited by 22 · see citing works
Dutasteride and Enzalutamide Synergistically Suppress Prostate Tumor Cell Proliferation
Hamid, A. R. A. H., Verhaegh, G. W. C. T., Smit, F. P., de Westerlo, C. V. R.-V., Armandari, I., Brandt, A. M., Sweep, F. C. G. J., Sedelaar, J. P. M., & Schalken, J. A. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.09.021 · Cited by 22 · see citing works
In touch with your feminine side: how oestrogen metabolism impacts prostate cancer
Rahman, H. P., Hofland, J., & Foster, P. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0118 · Cited by 21 · see citing works
Self-citation
A bypass mechanism of abiraterone‐resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling
Moll, J. M., Kumagai, J., van Royen, M. E., Teubel, W. J., van Soest, R. J., French, P. J., Homma, Y., Jenster, G. W., de Wit, R., & van Weerden, W. M. (2019) · The Prostate · doi:10.1002/pros.23799 · Cited by 21 · see citing works
Self-citation

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy
Armandari, I., Hamid, A. R. A. H., Verhaegh, G. W. C. T., & Schalken, J. A. (2014) · Prostate International · doi:10.12954/pi.14063 · Cited by 34 · see citing works
The role of adrenal derived androgens in castration resistant prostate cancer
Barnard, M., Mostaghel, E. A., Auchus, R. J., & Storbeck, K. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105506 · Cited by 67 · see citing works
Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer
Zhou, J., Wang, Y., Wu, D., Wang, S., Chen, Z., Xiang, S., & Chan, F. L. (2021) · Oncogene · doi:10.1038/s41388-021-01737-1 · Cited by 36 · see citing works
Development of prostate cancer in a patient with primary hypogonadism: intratumoural steroidogenesis in prostate cancer tissues
Arai, S., Shibata, Y., Nakamura, Y., Kashiwagi, B., Uei, T., Tomaru, Y., Miyashiro, Y., Honma, S., Hashimoto, K., Sekine, Y., et al. (2012) · Andrology · doi:10.1111/j.2047-2927.2012.00026.x · Cited by 11 · see citing works
Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747 · see citing works

Authors: Hofland, J., van Weerden, W. M., Dits, N. F. J., Steenbergen, J., van Leenders, G. J. L. H., Jenster, G., Schröder, F. H., & de Jong, F. H.
Affiliations: Erasmus MC (NL)
Authors' Affiliations: Departments of 1Internal Medicine, 2Urology, and 3Pathology, Erasmus MC, Rotterdam, the Netherlands
ORCID: Hofland, Johannes
Jenster, Guido
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-01-31
Volume: 70
Issue: 3
Pages: 1256-1264
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-09-2092
OpenAlex: W2099477169
Cited by: 176
References: 40
Citations by year: 2026: 3 · 2025: 1 · 2024: 3 · 2023: 6 · 2022: 4 · 2021: 11 · 2020: 6 · 2019: 6 · 2018: 10 · 2017: 10 · 2016: 7 · 2015: 10 · 2014: 25 · 2013: 21 · 2012: 20
FWCI: 20.47
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: other-oa
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
RePub (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords: prostate cancer, castration-resistant prostate cancer, androgen production, CYP17A1, HSD3B1, AKR1C3, SRD5A1, dihydrotestosterone, androgen deprivation therapy, steroidogenic enzyme expression, lymph node metastasis, CYP17 inhibition
MeSH terms: Aldo-Keto Reductase Family 1 Member C3, Aged, Aged, 80 and over, Androgens, Androstenedione, Animals, Humans, Hydroxyprostaglandin Dehydrogenases, Male, Middle Aged, Neoplasms, Experimental, Orchiectomy, Pregnenolone, Progesterone Reductase, Prostatic Neoplasms, RNA, Messenger, Dihydrotestosterone, Steroid 17-alpha-Hydroxylase, Testosterone, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase, Transplantation, Heterologous, 3-Hydroxysteroid Dehydrogenases, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Reverse Transcriptase Polymerase Chain Reaction, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks